MedTrace Logo

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

NCT01796964 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2016-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.

Conditions

  • Exudative Age-Related Macular Degeneration

Interventions

DRUG

ESBA1008 solution

For intravitreal (IVT) injection

DRUG

Aflibercept

For intravitreal (IVT) injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Manager, GCRA, Pharma · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-10-31
Completion
2014-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796964 on ClinicalTrials.gov